nach oben

Der Schmerz

Erschienen in:

07.06.2018 | Neuropathischer Schmerz | CME

Cannabinoide in der Schmerzmedizin

verfasst von: Prof. Dr. M. Karst

Erschienen in: Der Schmerz | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Endocannabinoidsystem (ECS) kontrolliert eine Vielzahl überlebenswichtiger Funktionen. Ein suboptimaler Tonus des ECS in bestimmten Regionen des Nervensystems wird mit Störungen assoziiert, die auch mit Schmerzen verbunden sind. Über die exogene Zufuhr von Cannabinoiden können Schmerz- und Entzündungsvorgänge moduliert werden. Randomisierte, kontrollierte Studien zeigten bei verschiedenen chronischen Schmerzen geringe bis mäßige, in Einzelfällen große schmerzlindernde Effekte. Personen mit chronischen neuropathischen Schmerzen und Stresssymptomen scheinen besonders zu profitieren. Die therapeutische Breite von Cannabinoiden ist gering, für klinisch bedeutsame Effekte reichen oft geringe Dosierungen. Das „Cannabis-als-Medizin-Gesetz“ erlaubt unter bestimmten Voraussetzungen die Verordnung von Cannabiszubereitungen. Vorliegende Daten weisen auf eine gute Langzeitwirksamkeit und Langzeitverträglichkeit hin. Systematische Langzeiterfahrungen aus klinischen Studien gibt es aber kaum.

Beaulieu P, Boulanger A, Desroches J, Clark AJ (2016) Medical cannabis: considerations for the anesthesiologist and pain physician. Can J Anesth 63:608–624CrossRef

Rätsch C (1998) Hanf als Heilmittel. AT Verlag, Aarau, S 10–121

Most GF (1843) Encyklopädie der gesamten Volksmedicin, oder Lexikon der vorzüglichsten und wirksamsten Haus- und Volksarzneimittel aller Länder. Brockhaus, Leipzig

Dixon WE (1899) The pharmacology of Cannabis indica. BMJ 2:1354–1357CrossRef

Ransom JJ (1999) “Anslingerian” politics: the history of anti-marijuana sentiment in federal law and how Harry Anslinger’s anti-marijuana politics continue to prevent the FDA and other medical experts from studying marijuana’s medical utility. Food and Drug Law. http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965561. Zugegriffen: 17. Febr. 2018

Mechoulam R, Shvo Y (1963) The structure of cannabidiol. Tetrahedron 19:2073–2078CrossRef

Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647CrossRef

Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, DiMarzo V et al (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36(5):277–296CrossRef

McPartland JM, Guy GW, DiMarzo V (2014) Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS ONE 9(3):e89566CrossRef

10.

Paunescu H, Coman OA, Coman L, Ghita I, Georgescu SR, Draghia F, Fulga I (2011) Cannabinoid system and cyclooxygenases inhibitors. J Med Life 4(1):11–20PubMedPubMedCentral

11.

Berger WT, Ralph BP, Kaczocha M, Sun J, Balius TE, Rizzo RC et al (2012) Targeting fatty acid binding protein (FABP) anandamide transporters – a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS ONE 7(12):e50968CrossRef

12.

Deutsch DG (2016) A personal retrospective: elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs). Front Pharmacol 7:370CrossRef

13.

Maejima T, Ohno-shosaku T, Kano M (2001) Endogenous cannabinoid as a retrograde messenger from postsynaptic neurons to presynaptic terminals. Neurosci Res 40:205–210CrossRef

14.

Mendiguren A, Aostri E, Pineda J (2018) Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects. Life Sci 192:115–127CrossRef

15.

Piazza PV, Cota D, Marsicano G (2017) The CB1 receptor as the cornerstone of exostasis. Neuron 93(6):1252–1274CrossRef

16.

Russo EB (2016) Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndroms. Cannabis Cannabinoid Res 1(1):154–165CrossRef

17.

Karst M, Wippermann S, Ahrens J (2010) Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 70(18):2409–2438CrossRef

18.

Lötsch J, Weyer-Menkhoff I, Tegeder I (2017) Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings. Eur J Pain. https://doi.org/10.1002/ejp.1148 CrossRefPubMed

19.

Agarwal N, Pacher P, Tegeder I et al (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870–879CrossRef

20.

Jhaveri MD, Sagar DR, Elmes SJR, Kendall DA, Chapman V (2007) Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 36:26–35CrossRef

21.

Wotherspoon GA, Fox P, McIntyre S et al (2005) Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 35:235–245CrossRef

22.

Zurier RB, Burstein SH (2016) Cannabinoids, inflammation, and fibrosis (2016). FASEB J 30(11):3682–3689CrossRef

23.

Ibrahim MM, Porreca F, Lai J et al (2005) CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102:3093–3098CrossRef

24.

Hohmann AG, Suplita RL, Bolton NM et al (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108–1112CrossRef

25.

Carlino E, Benedetti F (2016) Different contexts, different pains, different experiences. Neuroscience 338:19–26CrossRef

26.

Morena M, Patel S, Bains JS, Hill MN (2015) Neurobiological interactions between stress and the endocannabinod system. Neuropsychopharmacology 41(1):80–102CrossRef

27.

Hill MN, Lee FS (2016) Endocannabinoids and stress resilience: is deficiency sufficient to promote vulnerability? Biol Psychiatry 79(10):792–793CrossRef

28.

Karhson DS, Hardan AY, Parker KJ (2016) Endocannabinoid signaling in social functioning: an RDoC perspective. Transl Psychiatry 6(9):e905CrossRef

29.

Akerblom S, Perrin S, Rivano Fischer M, McCracken LM (2017) The impact of PTSD on functioning in patients seeking treatment for chronic pain and validation of the posttraumatic diagnostic scale. Int J Behav Med 24(2):249–259CrossRef

30.

Marsicano G, Wotjak CT, Azad SC et al (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–534CrossRef

31.

Fattore L, Melis M, Fadda P, Pistis M, Fratta W (2010) The endocannabinoid system and nondrug rewarding behaviors. Exp Neurol 224(1):23–36CrossRef

32.

Walker JM, Huang SM, Strangman NM et al (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96:12198–12203CrossRef

33.

Vachon-Presseau E, Centeno MV, Ren W, Berger SE, Tetreault P, Ghantous M et al (2016) The emotional brain as a predictor and amplifier of chronic pain. J Dent Res 95(6):605–612CrossRef

34.

Valverde O, Ledent C, Beslot F et al (2000) Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 12:533–539CrossRef

35.

Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74:1317–1324CrossRef

36.

Smith PA, Selley DE, Sim-Selley LJ, Welch SP (2007) Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 571:129–137CrossRef

37.

Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B et al (2017) Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology 42(9):1752–1765CrossRef

38.

Piper BJ, DeKeuster RM, Beals ML, Cobb CM, Burchman CA, Perkinson L et al (2017) Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol (Oxford) 31(5):569–575CrossRef

39.

Lee MC, Ploner M, Wiech K, Bingel U, Wanigasekera V, Brooks J, Menon DK, Tracey I (2013) Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 154:124–134CrossRef

40.

National Academies of Sciences, Engineering, and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. The National Academies Press, Washington, DC, S 1–487

41.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24):2456–2473CrossRef

42.

Aviram J, Samuelly-Leichtag G (2017) Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician 20(6):E755–E796PubMed

43.

Petzke F, Enax-Krumova EK, Häuser W (2016) Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies. Schmerz 30(1):62–88CrossRef

44.

Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A (2017) Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg 125(5):1638–1652CrossRef

45.

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W (2018) Cannabis-based medicines for chronic neuropathic pain in adults (Review). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD01282.pub2 CrossRefPubMed

46.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomized placebo-controlled trial. Lancet 362(9395):1517–1526CrossRef

47.

Grau-Lopez L, Sierra S, Martinez-Caceres E, Ramo-Tello C (2011) Analysis of the pain in multiple sclerosis patients. Neurologia 26(4):208–213CrossRef

48.

Ferraro D, Plantone D, Morselli F, Dallari G, Simone AM, Vitetta F et al (2018) Systematic assessment and characterization of chronic pain in multiple sclerosis patients. Neurol Sci 39:445–453CrossRef

49.

Scherder R, Kant N, Wolf ET, Pijnenburg B, Scherder EJ (2018) Psychiatric and physical comorbidities and pain in patients with multiple sclerosis. J Pain Res 11:325–334CrossRef

50.

Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA et al (2015) Inhaled cannabis for chronic neuropahic pain: a meta-analysis of individual patient data. J Pain 16(12):1221–1232CrossRef

51.

Häuser W, Fitzcharles MA, Radbruch L, Petzke F (2017) Cannabinoids in pain management and palliative medicine – an overview of systematic reviews and prospective observational studies. Dtsch Arztebl Int 114(38):627–634PubMedPubMedCentral

52.

Karst M, Passie T (2018) Considerable heterogeneity. Dtsch Arztebl Int 115(9):143PubMedPubMedCentral

53.

Fitzcharles MA, Baerwald C, Ablin J, Häuser W (2016) Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz 30(1):47–61CrossRef

54.

Mu A, Weinberg E, Moulin DE, Clarke H (2017) Pharmacologic management of chronic pain. Can Fam Physician 63(11):844–852PubMedPubMedCentral

55.

Gruccu G, Truini A (2017) A review of neuropathic pain: from guidelines to clinical practice. Pain Ther 6(Suppl 1):S35–S42

56.

La Porta C, Bura SA, Llorente-Onaindia J, Pastor A, Navarrete F, Garcia-Gutierrez MS et al (2015) Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain 156(10):2001–2012CrossRef

57.

Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH (2012) Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal 4(7–8):649–659CrossRef

58.

Steenkamp MM, Blessing EM, Galatzer-Levy IR, Hollahan LC, Anderson WT (2017) Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety 34(3):207–216CrossRef

59.

Lochte BC, Beletsky A, Samuel NK, Grant I (2017) The use of cannabis for headache disorders. Cannabis Cannabinoid Res 2(1):61–71CrossRef

60.

Hasenoehrl C, Storr M, Schicho R (2017) Cannabinoids for treating inflammatory bowel disease: where are we and where do we go? Expert Rev Gastroenterol Hepatol 11(4):329–337CrossRef

61.

Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders. Neurology 82:1556–1563CrossRef

62.

Grotenhermen F, Häußermann K (2017) Cannabis. Verordnungshilfe für Ärzte. Wissenschaftliche Verlagsgesellschaft, Stuttgart

63.

https://www.arbeitsgemeinschaft-cannabis-medizin.de/2017/12/28/__trashed-2/. letzte Änderung 20.02.2018, Zugegriffen: 22. Febr. 2018

64.

https://dacnrf.pharmazeutische-zeitung.de/index.php. Zugegriffen: 11. Febr. 2018

65.

Russo EB (2011) Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163(7):1344–1364CrossRef

66.

Tashkin DP (2013) Effects of marijuana smoking on the lung. Ann Am Thorac Soc 10(3):239–247CrossRef

67.

Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT (2013) An open-label extension study to investigate the long-term safety and tolerability of the THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 46:207–218CrossRef

68.

Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012) An efficient randomized, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153(9):1837–1846CrossRef

69.

Benson N, Metelkin E, Demin O, Li GL, Nichols D, van der Graaf PH (2014) A systems pharmacology perspective on the clinical development of fatty acid amide hydrolase inhibitors for pain. CPT Pharmacometrics Syst Pharmacol 3:e91CrossRef

70.

Mallet C, Dubray C, Duale C (2016) FAAH inhibitors in the limelight, but regrettably. Int J Clin Pharmacol Ther 54(7):498–501CrossRef

71.

Van Esbroeck ACM, Janssen APA, Cognetta AB 3rd, Ogasawara D, Shpak G, van der Kroeg M et al (2017) Acitivity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science 356(6342):1084–1087CrossRef

72.

https://clinicaltrials.gov/ct2/show/NCT03058562?cond=Tourette+Syndrome&cntry=DE&rank=1. Zugegriffen: 11. Febr. 2018

73.

Karst M, Wippermann S (2009) Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective. Expert Opin Investig Drugs 18(2):125–133CrossRef

74.

Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290(13):1757–1762CrossRef

75.

Salim K, Schneider U, Burstein S, Hoy L, Karst M (2005) Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 48(8):1164–1171CrossRef

76.

https://www.corbuspharma.com. Zugegriffen: 11. Febr. 2018

77.

https://clinicaltrials.gov/ct2/results?cond=&term=Palmitoylethanolamide&cntry=&state=&city=&dist=. Zugegriffen: 17. Febr. 2018

78.

Keppel Hesselink JM (2012) New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. Open Pain J 5:12–23CrossRef

79.

Karst M (2012) Chronische Schmerzen: Behandlung mit Palmitoylethanolamin. J Club Schmerzmed 2:96

80.

Zhornitsky S, Potvin S (2012) Cannabidiol in humans – the quest for therapeutic targets. Pharmaceuticals 5:529–552CrossRef

81.

Häußermann K, Wagner U (2017) Cannabidiol: der “rising star” unter den Cannabinoiden? Pharmakon 5(2):123–128

82.

Rukwied R, Watkinson A, McGlone F, Dvorak M (2003) Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102(3):283–288CrossRef

83.

Mounessa JS, Siegel JA, Dunnick CA, Dellavalle RP (2017) The role of cannabinoids in dermatology. J Am Acad Dermatol 77(1):188–190CrossRef

84.

Phan NQ, Siepmann D, Gralow I, Ständer S (2010) Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges 8(2):88–91CrossRef

Titel: Cannabinoide in der Schmerzmedizin
verfasst von: Prof. Dr. M. Karst
Publikationsdatum: 07.06.2018
Verlag: Springer Medizin
Schlagwörter: Neuropathischer Schmerz
Cannabinoide
Erschienen in: Der Schmerz / Ausgabe 5/2018
Print ISSN: 0932-433X
Elektronische ISSN: 1432-2129
DOI: https://doi.org/10.1007/s00482-018-0299-1

Neu im Fachgebiet AINS

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Cannabinoide in der Schmerzmedizin

Zusammenfassung

Neu im Fachgebiet AINS

Magen-Darm-Blutungen werden präklinisch oft falsch eingeschätzt

Sepsis-Verdacht: Eine Stunde, fünf essenzielle Maßnahmen

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Update AINS

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

President´s Corner (Mitteilungen der Deutschen Schmerzgesellschaft e.V.)

Postoperative Opioide: Das sind die Auswirkungen auf Immunantwort & endokrines System

Eine schwach negative Empfehlung ist kein kategorisches Nein

Die eigentliche Aufgabe

Morbus Parkinson, Morbus Alzheimer und onkologische Erkrankungen in der stationären Altenhilfe

Mobilitätseinschränkungen bei Altenheimbewohnern

Neu im Fachgebiet AINS

Magen-Darm-Blutungen werden präklinisch oft falsch eingeschätzt

Sepsis-Verdacht: Eine Stunde, fünf essenzielle Maßnahmen

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Update AINS